5-乙酰基-2-(甲磺酰氨基)苯甲酸甲酯 | 824937-52-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-乙酰基-2-(甲磺酰氨基)苯甲酸甲酯
• 英文名称: methyl 5-acetyl-2-[(methylsulfonyl)amino]benzoate
• 英文别名: 3-(methoxycarbonyl)-4'-(methylsulfonylamino)acetophenone；methyl 5-acetyl-2-(methanesulfonamido)benzoate
• CAS: 824937-52-2
• 化学式: C₁₁H₁₃NO₅S
• 分子量: 271.294
• InChiKey: AUSXYCLPNLMLGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  97.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-乙酰基-2-(甲磺酰氨基)苯甲酸甲酯 、 (R)-(+)-叔丁基亚磺酰胺 在 titanium(IV) tetraethanolate 、 sodium tetrahydroborate 、 甲醇 作用下， 以 四氢呋喃 为溶剂， 反应 19.5h， 以23%的产率得到ethyl 5-((1R)-1-{[(R)-tert-butylsulfinyl]amino}ethyl)-2-[(methyl-sulfonyl)amino]benzoate
  参考文献：
  名称：

  Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists

  摘要：

  这项发明提供了一个化合物的结构式(I)：其中A和B分别独立地为CR12或N；D和E分别独立地为CR9或N；R1代表(C1-C6)烷基；R2代表氢、卤素、羟基、(C1-C6)烷基、卤代(C1-C6)烷基、羟基(C1-C6)烷基、(C1-C6)氧烷基或(C1-C6)氧烷基-(C1-C6)烷基；R3、R4、R5、R6、R10和R11分别独立地代表氢、卤素、(C1-C6)烷基、卤代(C1-C6)烷基、(C1-C6)氧烷基、羟基(C1-C6)烷基或(C1-C6)氧烷基-(C1-C6)烷基；或者R3和R4一起与它们连接的碳原子形成一个3-至7-成员的碳环或杂环，其中一个或两个非相邻的碳原子可以选择性地被氧原子、硫原子或NH取代；R7和R9分别独立地代表氢、卤素、(C1-C6)烷基、卤代(C1-C6)烷基、羟基(C1-C6)烷基、(C1-C6)氧烷基、羟基(C1-C6)氧烷基、(C1-C6)氧烷基-(C1-C6)烷基、(C1-C6)氧烷基-(C1-C6)氧烷基、(C1-C6)烷基硫、(C1-C6)烷基亚硫基、(C1-C6)烷基磺基、NH2、[(C1-C6)烷基]NH—、[(C1-C6)烷基]2N—、H2N—(C1-C6)氧烷基、(C1-C6)烷基-NH—(C1-C6)氧烷基、[(C1-C6)烷基]2N(C1-C6)氧烷基；H2N—(C1-C6)氧烷基-(C1-C6)烷基、(C1C6)烷基-NH—(C1-C6)氧烷基-(C1-C6)烷基、[(C1-C6)烷基]2N(C1-C6)氧烷基-(C1-C6)烷基或含有至少一个氮原子的5-或6-成员杂环，R8代表卤素、(C1-C6)烷基、卤代(C1-C6)烷基、羟基(C1-C6)烷基、(C1-C6)氧烷基、羟基(C1-C6)氧烷基、(C1-C6)氧烷基-(C1-C6)烷基、(C1-C6)氧烷基-(C1-C6)氧烷基、卤代(C1-C6)烷基磺基、卤代(C1-C6)烷基亚硫基、卤代(C1-C6)烷基氧基、卤代(C1-C6)烷基硫基、[(C1-C6)烷基]NH—或[(C1-C6)烷基]2N—；或者当E为CR9时，R7和R8一起与它们连接的碳原子形成一个5-8成员的碳环或杂环，其中一个或两个非相邻的碳原子可以选择性地被氧、硫、N或NH基团取代，其中碳环或杂环未取代或取代有一个或多个取代基，每个取代基独立地选自羟基、(C1-C6)烷基、(C1-C6)氧烷基和羟基(C1-C6)烷基；R12代表氢、卤素、(C1-C6)烷基或羟基(C1-C6)烷基；或其药学上可接受的盐或溶剂。这些化合物对于治疗由VR1受体过度激活引起的疾病状况，如哺乳动物中的疼痛等，是有用的。这项发明还提供了包含上述化合物的药物组合物。

  公开号：

  US20060211741A1

文献信息

• AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME
  申请人：Shishido Yuji

  公开号：US20120088746A1

  公开（公告）日：2012-04-12

  Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

  披露了具有以下公式表示的化合物：公式（I）。这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如疼痛、炎症、创伤性损伤等。
• [EN] 4-(METHYL SULFONYL AMINO) PHENYL ANALOGUES AS VANILLOID ANTAGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] ANALOGUES DE 4-(METHYL SULFONYL AMINO)PHENYLE UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR VANILLOIDE AYANT UNE EXCELLENTE ACTIVITE ANALGESIQUE, ET COMPOSITIONS PHARMACEUTIQUE LES COMPRENANT
  申请人：DIGITALBIOTECH CO LTD

  公开号：WO2005003084A1

  公开（公告）日：2005-01-13

  The present invention relates to novel 4-(methylsulfonylamino) phenyl analogue as a potent vanilloid receptor antagonist and the pharmaceutical compositions comprising the same. The inventive compound can be useful for analgesics to prevent, alleviate or treat pain diseases or inflammatory disease comprising pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease and urgent urinary incontinence.

  本发明涉及一种新型的4-(甲磺胺基)苯基类似物，作为有效的辣椒素受体拮抗剂，以及包含该类似物的药物组合物。这种创新化合物可用于镇痛药，用于预防、缓解或治疗疼痛疾病或包括疼痛的炎症性疾病，如急性疼痛、慢性疼痛、神经痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病性神经病、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合征、哮喘或慢性阻塞性肺疾病等呼吸道疾病、皮肤、眼睛或粘膜的刺激、发热、胃十二指肠溃疡、炎症性肠病、炎症性疾病和急性尿失禁。
• Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists
  申请人：Hanazawa Takeshi

  公开号：US20060205980A1

  公开（公告）日：2006-09-14

  This invention provides a compound of the formula (I): wherein R 1 represents (C 1 -C 6 )alkyl; R 2 represents a hydrogen atom, a halogen atom, a hydroxy group, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl or halo(C 1 -C 6 )alkyl; R 3 represents a halogen atom, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl, (C 1 -C 6 )alkylsulfonyl, [(C 1 -C 6 )alkyl]NH—, or [(C 1 -C 6 )alkyl] 2 N—; R 4 represents a halogen atom, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, [(C 1 -C 6 )alkyl]NH—, or [(C 1 -C 6 )alkyl] 2 N—; R 5 represents a halogen atom, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl, (C 1 -C 6 )alkylsulfonyl, [(C 1 -C 6 )alkyl]NH—, [(C 1 -C 6 )alkyl] 2 N—, H 2 N—(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl-NH—(C 1 -C 6 )alkoxy, [(C 1 -C 6 )alkyl] 2 N(C 1 -C 6 )alkoxy, H 2 N—(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl-NH—(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, or [(C 1 -C 6 )alkyl] 2 N(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl; and * indicates a chiral centre; or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了一种化合物的公式（I）： 其中，R1代表（C1-C6）烷基；R2代表氢原子，卤素原子，羟基，（C1-C6）烷基，（C1-C6）烷氧基，羟基（C1-C6）烷基，（C1-C6）烷氧基-（C1-C6）烷基或卤代（C1-C6）烷基；R3代表卤素原子，（C1-C6）烷基，（C1-C6）烷氧基，羟基（C1-C6）烷氧基，（C1-C6）烷氧基-（C1-C6）烷基，（C1-C6）烷氧基-（C1-C6）烷氧基，卤代（C1-C6）烷基，（C1-C6）烷基硫醇，（C1-C6）烷基亚砜基，（C1-C6）烷基磺酰基，[(C1-C6)烷基]NH—或[(C1-C6)烷基]2N—；R4代表卤素原子，（C1-C6）烷基，卤代（C1-C6）烷基，（C1-C6）烷氧基，羟基（C1-C6）烷氧基，（C1-C6）烷氧基-（C1-C6）烷基，（C1-C6）烷氧基-（C1-C6）烷氧基，[(C1-C6)烷基]NH—或[(C1-C6)烷基]2N—；R5代表卤素原子，（C1-C6）烷基，（C1-C6）烷氧基，羟基（C1-C6）烷氧基，（C1-C6）烷氧基-（C1-C6）烷基，（C1-C6）烷氧基-（C1-C6）烷氧基，卤代（C1-C6）烷基，（C1-C6）烷基硫醇，（C1-C6）烷基亚砜基，（C1-C6）烷基磺酰基，[(C1-C6)烷基]NH—，[(C1-C6)烷基]2N—，H2N—（C1-C6）烷氧基，（C1-C6）烷基-NH—（C1-C6）烷氧基，[(C1-C6)烷基]2N（C1-C6）烷氧基，H2N—（C1-C6）烷氧基-（C1-C6）烷基，（C1-C6）烷基-NH—（C1-C6）烷氧基-（C1-C6）烷基或[(C1-C6)烷基]2N（C1-C6）烷氧基-（C1-C6）烷基；*表示一个手性中心；或其药学上可接受的盐或溶剂。 这些化合物可用于治疗哺乳动物中由VR1受体过度激活引起的疾病状况，例如疼痛等。本发明还提供了包含上述化合物的药物组合物。
• 4-(Methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same
  申请人：Lee Woo Jee

  公开号：US20060258884A1

  公开（公告）日：2006-11-16

  4-(methylsulfonylamino)phenyl analogues as potent vanilloid receptor antagonists and pharmaceutical compositions comprising the same. The compounds are useful as analgesics to prevent, alleviate or treat pain diseases or inflammatory disease including pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease and urgent urinary incontinence.

  4-(甲基磺酰氨基)苯类似物作为有效的vanilloid受体拮抗剂和包含它们的制药组合物。这些化合物可用作镇痛剂，以预防、缓解或治疗疼痛疾病或炎症性疾病，包括疼痛、急性疼痛、慢性疼痛、神经病性疼痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病神经病变、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合征、呼吸系统疾病，如哮喘或慢性阻塞性肺病、皮肤、眼睛或黏膜刺激、发热、胃十二指肠溃疡、炎症性肠病、炎症性疾病和紧急的尿失禁。
• SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS
  申请人：HANAZAWA TAKESHI

  公开号：US20100035880A1

  公开（公告）日：2010-02-11

  This invention provides a compound of the formula (I): wherein A and B are independently CR 12 or N; D and E are each independently CR 9 or N; R 1 represents (C 1 -C 6 )alkyl; R 2 represents hydrogen, halogen, hydroxy, (C 1 -C 6 ) alkyl, halo(C 1 -C 6 ) alkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy or (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl; R 3 , R 4 , R 5 , R 6 , R 10 and R 11 each independently represent hydrogen, halogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkyl or (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl; or R 3 and R 4 are taken together with the carbon atom to which they are attached to form a 3- to 7-membered carbocyclic ring or heterocyclic ring in which one or two non-adjacent carbon atoms are optionally replaced by an oxygen atom, a sulfur atom or NH; R 7 and R 9 each independently represent hydrogen, halogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl, (C 1 -C 6 )alkylsulfonyl, NH 2 , [(C 1 -C 6 )alkyl]NH—, [(C 1 -C 6 )alkyl] 2 N—, H 2 N—(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl-NH—(C 1 -C 6 )alkoxy, [(C 1 -C 6 )alkyl] 2 N(C 1 -C 6 )alkoxy; H 2 N—(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl-NH—(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, [(C 1 -C 6 )alkyl] 2 N(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl or 5- or 6-membered heterocyclic ring containing at least one nitrogen atom; R 8 represents halogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 8 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkylsulfonyl, halo(C 1 -C 6 )alkylsulfinyl, halo(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkylthio, [(C 1 -C 6 )alkyl]NH— or [(C 1 -C 6 )alkyl] 2 N—; or R 7 and R 8 , when E is CR 9 , are taken together with the carbon atoms to which they are attached form a 5-8 membered carbocyclic or heterocyclic ring, in which one or two non-adjacent carbon atoms are optionally replaced by oxygen, sulfur, N or NH groups, wherein the carbocyclic ring or the heterocyclic ring is unsubstituted or substituted with one or more substituents each independently selected from the group consisting of hydroxy, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy and hydroxy(C 1 -C 6 )alkyl; and R 12 represents hydrogen, halogen, (C 1 -C 6 )alkyl or hydroxy(C 1 -C 6 )alkyl; or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了一种公式（I）的化合物：其中A和B分别独立表示CR12或N; D和E分别独立表示CR9或N; R1表示（C1-C6）烷基; R2表示氢，卤素，羟基，（C1-C6）烷基，卤代（C1-C6）烷基，羟基（C1-C6）烷基，（C1-C6）氧烷基或（C1-C6）氧烷基-（C1-C6）烷基; R3、R4、R5、R6、R10和R11分别独立表示氢，卤素，（C1-C6）烷基，卤代（C1-C6）烷基，（C1-C6）氧烷基，羟基（C1-C6）烷基或（C1-C6）氧烷基-（C1-C6）烷基; 或R3和R4与它们所附着的碳原子一起形成3-至7-成员的碳环或杂环，其中一个或两个非相邻的碳原子可以选择地被氧原子，硫原子或NH代替; R7和R9分别独立表示氢，卤素，（C1-C6）烷基，卤代（C1-C6）烷基，羟基（C1-C6）烷基，（C1-C6）氧烷基，羟基（C1-C6）氧烷基，（C1-C6）氧烷基-（C1-C6）烷基，（C1-C6）氧烷基-（C1-C6）氧烷基，（C1-C6）烷基硫，（C1-C6）烷基亚磺酰基，（C1-C6）烷基磺酰基，NH2，[(C1-C6)烷基] NH-，[(C1-C6)烷基] 2N-，H2N-（C1-C6）氧烷基，（C1-C6）烷基-NH-（C1-C6）氧烷基，[(C1-C6)烷基] 2N（C1-C6）氧烷基; H2N-（C1-C6）氧烷基-（C1-C6）烷基，（C1-C6）烷基-NH-（C1-C6）氧烷基-（C1-C6）烷基，[(C1-C6)烷基] 2N（C1-C6）氧烷基-（C1-C6）烷基或含有至少一个氮原子的5-或6-成员杂环，R8表示卤素，（C1-C6）烷基，卤代（C1-C6）烷基，羟基（C1-C6）烷基，（C1-C6）氧烷基，羟基（C1-C6）氧烷基，（C1-C8）氧烷基-（C1-C6）烷基，（C1-C6）氧烷基-（C1-C6）氧烷基，卤代（C1-C6）烷基磺酰基，卤代（C1-C6）烷基亚磺酰基，卤代（C1-C6）氧烷基，卤代（C1-C6）烷基硫，[(C1-C6)烷基] NH-或[(C1-C6)烷基] 2N-; 或者当E为CR9时，R7和R8与它们所附着的碳原子一起形成5-8成员的碳环或杂环，其中一个或两个非相邻的碳原子可以选择地被氧，硫，N或NH基团代替，其中碳环或杂环未被取代或被一个或多个取代基取代，每个取代基独立地选择自羟基，（C1-C6）烷基，（C1-C6）氧烷基和羟基（C1-C6）烷基; R12表示氢，卤素，（C1-C6）烷基或羟基（C1-C6）烷基; 或其药学上可接受的盐或溶剂。这些化合物对于治疗由VR1受体过度激活引起的疾病状况，如哺乳动物中的疼痛等非常有用。本发明还提供了包含上述化合物的药物组成物。